LXRX Past Earnings image   This LXRX past earnings page last updated 11/10/2022
LXRX Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/9/2022-0.130
Q2 20228/2/2022-0.160
Q1 20225/5/2022-0.160
Q4 20212/28/2022-0.170
Q3 202111/3/2021-0.160
Q2 20217/30/2021-0.130
Q1 20215/6/2021-0.150
Q4 20203/10/2021-0.040
Q3 202010/29/2020-0.430
Q2 20207/30/2020-0.650
Q1 20204/27/2020-0.630
Q4 20193/12/2020-0.480
Q3 201911/7/2019-0.100
Q2 20197/31/2019-0.220
Q1 20195/1/2019-0.210
Q4 20183/13/2019-0.16
Q3 201811/1/2018-0.26
Q2 20187/30/2018-0.33
Q1 20185/3/2018-0.4
Q4 20172/22/2018-0.23
Q3 201711/8/2017-0.29
Q2 20178/1/2017-0.33
Q1 20175/2/2017-0.33
Q4 20163/3/2017-0.31
Q3 201611/1/2016-0.35
Q2 20168/4/2016-0.37
Q1 20165/3/2016-0.34
Q4 20153/1/20160.76
Q3 201511/6/2015-0.34
Q2 20158/7/2015-0.27
Q1 20154/29/2015-0.280
Q4 20143/4/20150
Q3 201411/4/2014-0.560
Q2 20148/7/2014-0.350
Q1 20145/8/2014-0.420
Q4 20132/17/2014-11.900
Q3 201311/6/2013-0.420
Q2 20137/30/2013-0.420
Q1 20135/10/2013-0.350
Q4 20122/21/2013-0.350
LXRX Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/9/20220.04M
Q2 20228/2/20220.04M
Q1 20225/5/20220.04M
Q4 20212/28/20220.01M
Q3 202111/3/20210.02M
Q2 20217/30/20210.00B
Q1 20215/6/20210.03M
Q4 20203/10/20210.00B
Q3 202010/29/20200.01B
Q2 20207/30/20200.01B
Q1 20204/27/20200.01B
Q4 20193/12/20200.01B
Q3 201911/7/20190.29B
Q2 20197/31/20190.01B
Q1 20195/1/20190.01B
Q4 20183/13/201917.07M
Q3 201811/1/20186.86M
Q2 20187/30/201813.75M
Q1 20185/3/201825.21M
Q4 20172/22/201833.05M
Q3 201711/8/201726.94M
Q2 20178/1/201712.05M
Q1 20175/2/201718.29M
Q4 20163/3/201723.04M
Q3 201611/1/201627.72M
Q2 20168/4/201620.09M
Q1 20165/3/201612.49M
Q4 20153/1/2016127.28M
Q3 201511/6/2015566000
Q2 20158/7/2015376000
Q1 20154/29/20151.79M
Q4 20143/4/201521.48M
Q3 201411/4/2014400000
Q2 20148/7/2014676000
Q1 20145/8/2014300000
Q4 20132/17/20141.41M
Q3 201311/6/20130.00B
Q2 20137/30/2013214000
Q1 20135/10/2013400000
Q4 20122/21/20130.00B
Quotes delayed 20 minutes

Email EnvelopeFree LXRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Lexicon Pharmaceuticals (LXRX) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

LYEL Past Earnings
LYRA Past Earnings
MACK Past Earnings
MASI Past Earnings
MBIO Past Earnings
MBOT Past Earnings
MBRX Past Earnings
MCK Past Earnings
MCRB Past Earnings
MD Past Earnings

LXRX Past Earnings Q&A

What was the best and worst LXRX past earnings results?
For Lexicon Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest LXRX past earnings result in our data set was 0.76/share posted in Q4 2015, while the lowest was in Q4 2013 when LXRX posted -11.900/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q3 2019 when LXRX reported 0.29B in revenue, while the quarter with the lowest revenue in our data set was Q4 2021 at 0.01M of revenue.

  Suggested answer: There are 40 LXRX past earnings results in our data set.

On this page we presented the LXRX past earnings date information for Lexicon Pharmaceuticals. Reviewing that LXRX Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2015, when LXRX posted gaap of 0.76/share. Meanwhile the lowest LXRX past earnings result was in Q4 2013, when LXRX posted gaap of -11.900/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2019 when LXRX reported 0.29B in revenue, while the smallest revenue quarter was Q4 2021 when LXRX reported 0.01M in revenue.

Any self directed investor doing their due diligence on LXRX or any other given stock can benefit from researching all of the Lexicon Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Lexicon Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for LXRX. Thanks for visiting, and the next time you need to research LXRX past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: VYGG YTD Return, Institutional Holders of Xylem, EYPT Insider Buying.

 

LXRX Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.